Achieve Life Sciences (ACHV) stock surged 42%, aiming for its best day since 2019. The rally followed the appointment of CEO Andrew D Goldberg and a $354 million private placement. Achieve focuses on securing FDA approval for its nicotine dependence drug cytisinicline, targeting a first-half 2027 launch.